| Wednesday, October 31, 2007 | ||
| 7:15 a.m. - 8:45 a.m. | Educational Session 401 Room 408 Breast Cancer Management Part II: Adjuvant Systemic Therapy and Loco-regional Radiotherapy in Stage I/II Breast Cancer |
Julie R. Gralow, M.D., Seattle Cancer Care Alliance, Seattle |
| 7:15 a.m. - 8:45 a.m. | Educational Session 402 Room 406 Image-guided Brachytherapy |
Cynthia Ménard, M.D., PMH-UHN-University of Toronto, Toronto, Ontario, Canada Richard Pötter, M.D., University Clinic for Radiotherapy and Radiobiology, Vienna, Austria Jeffrey Williamson, Ph.D., Virginia Commonwealth University, Richmond, Va. |
| 7:15 a.m. - 8:45 a.m. | Educational Session 403 Room 404 Brain Metastases |
Gene H. Barnett, M.D., Cleveland Clinic Foundation, Cleveland John H. Suh, M.D., Cleveland Clinic Foundation, Cleveland |
| 7:15 a.m. - 8:45 a.m. | Educational Session 404 Room 502 Nasopharyngeal Cancer |
Brian O’Sullivan, M.D., Princess Margaret Hospital, Toronto, Ontario, Canada Anne W.M. Lee, M.B.B.S., Pamela Youde Nethersole Eastern Hospital, Chaiwan, Hong Kong |
| 7:15 a.m. - 8:45 a.m. | Educational Session 405 The Theater Lung Cancer- NSCLC |
Jeffrey D. Bradley, M.D., Washington University Medical School, St. Louis Ramaswamy Govindan, M.D., Washington University, St. Louis |
| 7:15 a.m. - 8:45 a.m. | Educational Session 406 Room 409 In defense of Cure: The Arguments in Favor of Using Radiotherapy in HL and NHL in 2007 |
Theodore Girinsky, M.D., Institut Gustave-Roussy, Cedex, France Joachim Yahalom, M.D., Memorial Sloan-Kettering Cancer Center, New York |
| 7:15 a.m. - 8:45 a.m. | Educational Session 407 Room 403 Management of Localized High-risk Prostate Cancer |
Ronald Ennis, M.D., St. Lukes-Roosevelt Hospital, New York Daniel Shasha, M.D., Beth Israel Medical Center, New York |
| 7:15 a.m. - 8:45 a.m. | Educational Session 408 Room 405 Molecular Mechanisms of Cell Death: Apoptosis, Necrosis, Scenescence |
Jacqueline Patricia Williams, Ph.D., University of Rochester Medical Center, Rochester, N.Y. |
| 7:15 a.m. - 8:45 a.m. | Educational Session 409 Room 515B Image Guided Radiation Therapy: 4-D Treatment Approaches |
David Jaffray, Ph.D., Princess Margaret Hospital, Toronto, Ontario, Canada Paul J. Keall, Ph.D., Stanford University, Stanford, Calif. |
| 7:15 a.m. - 8:45 a.m. | Educational Session 410 Interactive Session Room 515A Difficult Cases in GYN Management |
Kaled M. Alektiar, M.D., Memorial Sloan-Kettering Cancer Center, New York Patricia J. Eifel, M.D., M.D. Anderson Cancer Center, Houston Anuja Jhingran, M.D., M.D. Anderson Cancer Center, Houston Arno J. Mundt, M.D., University of California San Diego, San Diego Wui-Jin Koh, M.D., University of Washington, Seattle |
| 9:00 a.m. - 10:00 a.m. | Keynote II Concourse Hall Intoduction |
Stephen M. Hahn, M.D., University of Pennsylvania, Philadelphia |
| Molecular Diagnostic Approaches in Cancer from Bench to Bedside Clonal genetic alterations including gene mutations, epigenetic alterations or mitochondrial changes are a hallmark of human cancer. These genetic alterations can be detected in clinical samples using DNA amplification techniques and used to estimate tumor burden and for the early detection of cancer. Moreover, these alterations can be tested by molecular techniques in clinical trials materials to provide better estimates of prognosis and prediction of therapy. Individualized models can also help integrate such markers and help define new combinations of novel and standard drugs. Biomarkers of sensitivity and resistance will emerge from these studies and will help guide personalized therapy with more success and less toxicity. |
David Sidransky, M.D., Johns Hopkins School of Medicine, Baltimore | |
| 10:15 a.m. - 11:45 a.m. | Poster Discussion 7 Room 515B Radiation Physics |
Co-moderators: Joseph Deasy Michael Gillin Timothy Solberg |
| 10:15 a.m. - 11:45 a.m. | Scientific Session P Room 502 Breast II - Radiation Techniques and PMRT |
Co-moderators: Jennifer Bellon Pauline Truong |
| 126 - Placement of Radiopaque Clips for Tumor Localization in Patients Undergoing Neoadjuvant Chemotherapy and Breast Conservation Therapy Improves Local Control | Welela Tereffe | |
| 127 - Variability of Target and Normal Structure Delineation for Breast Cancer Radiotherapy: A RTOG Multi-institutional and Multi-observer Study | X. Li | |
| 128 - Prone Positioning Causes the Heart to be Displaced Anteriorly within the Thorax: Implications for Breast Cancer Treatment | Junzo Chino | |
| 129 - Prospective Trial of Individual Optimal Positioning (Prone vs. Supine) for Whole Breast Radiotherapy: Results of the First 168 Patients | Silvia Formenti | |
| 130 - Chronic Breast Pain after Breast-conserving Therapy | Jorgen Johansen | |
| 131 - Malignant Phyllodes Tumor of the Breast: Local Control Rates with Surgery Alone | Richard Pezner | |
| 132 - Post-mastectomy Chest Wall Radiation to a Temporary Tissue Expander or Permanent Breast Implant - Is There a Difference in Complication Rates? | Penny Anderson | |
| 133 - Impact of Postoperative Radiation Therapy on Post-mastectomy Breast Reconstruction | Louis Keiler | |
| 134 - Chest Wall Radiation Alone for Breast Cancer Patients with 1-3 Positive Lymph Nodes Treated by Mastectomy | Rita Abi-Raad | |
| 10:15 a.m. - 11:45 a.m. | Scientific Session Q The Theater GI I - Pancreas/Liver |
Co-moderators: Edgar Ben-Josef Sunil Krishnan |
| 135 - Definitive Results of the French FFCD-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin And Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer | Francoise Mornex | |
| 136 - A Phase II Study of Bevacizumab with Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: RTOG PA0411 | Christopher Crane | |
| 138 - Adjuvant Radiation and Chemotherapy for Pancreatic Adenocarcinoma: The Mayo Clinic Experience | Michele Corsini | |
| 139 - Neoadjuvant Candidate Score for Multidisciplinary Treatment of Pancreatic Adenocarcinoma: Identifying Candidates Among Individuals After Pancreaticoduodenectomy with Curative Intent | Charles Hsu | |
| Discussant 135-139: Jerome Landry |
||
| 140 - Liver Function after Irradiation Based Upon CT Portal Venous Perfusion Imaging | Yue Cao | |
| 141 - Liver Regeneration in Patients with Intrahepatic Malignancies Treated with Focal Liver Radiation Therapy | Charlie Pan | |
| Discussant 140-141: Chandan Guha |
||
| 10:15 a.m. - 11:45 a.m. | Scientific Session R Room 408 GU II - External Beam/ Brachytherapy for Prostate Cancer |
Co-moderators: Michael Hagan Scott Williams |
| 142 - Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer | Abrahim Al-Mamgani | |
| 143 - Surrogate Endpoints for Prostate Cancer Survival: A Secondary Analysis of RTOG 9202 | Michael Ray | |
| 144 - Radiation Therapy in Prostate Cancer Patients and Survival - A Population-based Study | Ester Zhou | |
| 145 - Does Image Guidance Need to be Performed Daily in the Treatment of Localized Prostate Cancers? Implications on Treatment Margins | Sanford Meeks | |
| 146 - High-dose-rate Brachytherapy (HDR-BT) as Monotherapy for Favorable Prostate Cancer: Excellent 5-year Control Rates and Low Toxicity | D. Demanes | |
| 147 - 10-year Results in 1577 Intermediate/High-risk Prostate Cancer Patients Treated with External Beam RT (EBRT) and Hypofractionated High-dose-rate (HDR) Brachytherapy Boost | Michel Ghilezan | |
| 148 - Improved 10-year Outcomes for Prostate Cancer Patients with Gleason 8-10 Treated with Intensity Modulated High-dose-rate Brachytherapy Boost in the PSA Era | Todd Swanson | |
| 149 - Combined Treatment 3D-conformal Radiotherapy Plus HDR Brachytherapy as Treatment for Intermediate- or High-risk Prostate Cancer: Early Toxicty and Biochemical Outcome of a Dose-escalation Prospective Randomized Trial | Benjamin Guix | |
| 150 - Multicenter Analysis of Impact of High Biologically Effective Dose (BED) on Biochemical Failure (Phoenix Definition) and Survival Outcomes in Patients with Gleason Score 7-10 Prostate Cancer Treated by Permanent Prostate Brachytherapy | Nelson Stone | |
| 10:15 a.m. - 11:45 a.m. | Scientific Session S Room 403 Lung II - SBRT/IGRT |
Co-moderators: Roy Decker Ramesh Rengan |
| 151 - Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early-stage Lung Cancer Patients | Robert Timmerman | |
| 152 - Stereotactic Body Radiotherapy (SBRT, BED>100Gy) for Operable Stage I Non-small Cell Lung Cancer: Is SBRT Comparable to Surgery? | Hiroshi Onishi | |
| 153 - Comparison of Prescription Methods for Stereotactic Body Radiotherapy in Lung Cancer | Kenneth Olivier | |
| 154 - Outcome After Stereotactic Radiotherapy in ‘High-risk’ Patients with Stage I Non-small Cell Lung Cancer (NSCLC) | Frank Lagerwaard | |
| Discussant 151-154: Martin Fuss |
||
| 155 - Image Guided, Intensity Modulated Hypofractionated Radiotherapy for Inoperable Non-small Cell Lung Cancer: Preliminary Results of a Phase I Dose Escalation Study | Jarrod Adkison | |
| 156 - 4D-CT Based and Daily In-room CT-guided Stereotactic Body Radiotherapy (SBRT) for Lung Cancer | Joe Chang | |
| 157 - Radiographic and Metabolic Response of Solitary Lung Tumors to Image Guided Stereotactic Radiotherapy | K. Chao | |
| Discussant 155-157: Jeffrey Bradley |
||
| 10:15 a.m. - 11:45 a.m. | Scientific Session T |
Co-moderators: |
| 158 - Provider Volume and Outcomes Following Prostate Brachytherapy | Aileen Chen | |
| 159 - The Influence of Serial Prostate-specific Antigen Screening on the Pre-diagnostic PSA Velocity Level at Diagnosis | Neil Martin | |
| 160 - Young Men Have Equivalent Biochemical Outcomes Compared to Older Men After Treatment with Prostate Brachytherapy | Alice Ho | |
| 161 - Tertiary Gleason Grade 5 on Prostate Needle Biopsy and Recurrence Following Definitive Therapy in Men with Gleason Score 7 Prostate Cancer | Abhijit Patel | |
| 162 - Cost-effectiveness of Routine Radiation Therapy when Added to Tamoxifen Following Conservative Surgery in Older Women with Early-stage Breast Cancer | Jonathan Patrice | |
| 163 - Partial-breast Irradiation vs. Whole Breast Irradiation for Early-stage Breast Cancer: A Decision Analysis | David Sher | |
| 164 - Sargramostim (Leukine/ GM-CSF) for Autologous (Au) or Allogeneic (Allo) Bone Marrow Transplant (BMT) Engraftment Delay or Failure (ED/F) After Total Body Irradiation Conditioning (TBI) | L. O'Neal | |
| 165 - How Often are Previously Undetected Radiographic Abnormalities Detected at the Time of CT Simulation? | Anushka Patel | |
| 166 - Utilization of Radiotherapy for Palliation of Bone Metastases: A 3-year Patterns of Practice Study at a Regional Cancer Centre | Jackson Wu | |
| 10:15 a.m. - 11:45 a.m. | Scientific Session U Room 405 Sarcoma |
Moderator: Sue Yom |
| 167 - Patterns of Morbidity by Compartments in Soft Tissue Sarcoma (STS) of the Thigh | Andreas Rimner | |
| 168 - Long-term Outcomes in Extremity Soft Tissue Sarcoma (STS) After a Pathologically Negative Re-resection and without Radiotherapy (RT) | Oren Cahlon | |
| 169 - Percent Necrosis in Extremity Soft Tissue Sarcoma After Preoperative Radiation Alone vs. Preoperative Radiation and Chemotherapy | Karl Haglund | |
| 170 - Carbon Ion Radiotherapy for Unresectable Retroperitoneal Sarcomas | Tadashi Kamada | |
| 171 - Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature | James Murphy | |
| Discussants: Elizabeth Baldini Eli Glatstein |
||
| 10:15 a.m. - 11:45 a.m. | Scientific Session V |
Co-moderators: Fred Bunz David Gius |
| 172 - Noninvasive Monitoring of Ligand-dependent VEGF Receptor-2 Dimerization with Split Firefly Luciferase | Percy Lee | |
173 - Radiation Enhances Pancreatic Cancer Invasion Through a Plasma Fibronectin (pFn)-dependent, Fibronectin Receptor (FnR)-mediated Pathway that May Involve WNT Signaling |
Donna Livant | |
| 174 -ß1 Integrin Inhibition Enhances Apoptosis Post-ionizing Radiation (ir) in Breast Cancer in 3-Dimensional Culture and In Vivo | Catherine Park | |
| 175 - SF1126, a Novel Integrin-targeting Phosphatidylinositol-3 Kinase Inhibitor, has Radiosensitizing and Anti-tumor Effects in Glioma Model Systems | Hui-Kuo Shu | |
| 176 - Survival Signaling Through Nuclear Epidermal Growth Factor Receptor and STAT3 Mediates Photodynamic Therapy Resistance in Ovarian and Lung Cancer Cells | Keith Cengel | |
| 177 - Caspase-3/7 Deficiency Promotes ER Stress-induced Autophagy via PERK-eIF2a Under Ionizing Radiation | Kwang Woon Kim | |
| 178 - Sensitization of a Glioblastoma Multiforme (GBM) Cell Line by MP470: A Novel c-Met Antagonist | James Welsh | |
| 179 - Radiosensitization of Pancreatic Cancer-recruited Endothelial Cells by Enzastaurin, an Inhibitor of PKCß | Aaron Spalding | |
| 180 - PKC(epsilon) Regulates Radiation Induced Akt Activation via Myristoylated Alanine Rich C Kinase Substrate (MARCKS) in Vascular Endothelium | Christopher Willey | |
| 10:15 a.m. - 11:45 a.m. | Educational Session 411 Room 511 Adult Brain Tumors |
Minesh P. Mehta, M.D., University of Wisconsin, Madison, Wis. C. Leland Rogers, M.D., GammaWest Radiation Therapy, Salt Lake City |
| 10:15 a.m. - 11:45 a.m. | Educational Session 412 Room 406 Quality of Life Issues and the Role for Radiation Therapy for the Palliative Care Patient |
Edward Chow, M.D., Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada Linda A. Filipczak, R.N., B.S.N., M.B.A., 21st Century Oncology, Plymouth, Mich. |
| 11:45 a.m. - 1:00 p.m. | Government Relations Luncheon Room 501 The Government Relations Council is pleased to present ASTRO’s outside counsel to review recent regulatory interest in troublesome self-referral arrangements and ASTRO’s efforts to remove radiation therapy from the in-office ancillary services exception. |
John Brennan, Esq. Kathleen Stratton, Esq. |
| 11:45 a.m. - 1:00 p.m. | ARRO Meet the Professor Luncheon Room 515 |
|
| 1:00 p.m. - 2:30 p.m. | Poster Discussion 8 Room 515B Head and Neck |
Co-moderators: Jonathan Beitler Vijay Kini |
| 1:00 p.m. - 2:30 p.m. | Scientific Session W Room 404 CNS II |
Co-moderators: Iris Gibbs Paul Sperduto |
| 181 - Predictive Value of 11-C Methionine Positron Emission Tomography in Assessing Treatment Response Following Concurrent Temozolomide/RT in Primary Glioblastoma Multiforme | Christina Irene Tsien | |
| 182 - Patterns of Failure in Primary GBM Following High-dose Radiation Therapy and Concurrent Temozolomide, Indicating a Potential Role for Methionine-PET in GTV Definition | Irwin Lee | |
| 183 - C11-Methionine-PET Based Substrate for Target Definition in Stereotactic Radiosurgery of Brain Metastases | Masayuki Matsuo | |
| 184 - Neurocognitive Impact of Whole Brain Radiation on Patients with Brain Metastases: Secondary Analysis of RTOG BR-0018 | Young Kwok | |
| 185 - Be Careful with Predamaged Brain: Differences in Memory Function Before and After Whole Brain Radiation Therapy in Patients with and without Brain Metastases | Grit Welzel | |
| 186 - Spinal Cord Astrocytomas: Treatment Considerations | Kiernan Minehan | |
| 187 - Radiosurgery for Spinal Cord Arteriovenous Malformations | Scott Soltys | |
| 188 - Risk Factors for Inter-fraction Tissue Motion during Cranial Radiation Therapy | Todd Jenkins | |
| 189 - Modification of Brain Tumor Microenvironment by Applying Cervical Spinal Cord Stimulation (cSCS) | Bernardino Clavo | |
| 1:00 p.m. - 2:30 p.m. | Scientific Session X Room 408 GI II - Gastroesophageal/Rectal |
Co-moderators: Leonard Gunderson Te Vuong |
| 190 - A Phase II Study of a Paclitaxel Based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246 | Stephen Swisher | |
| 191 - Does the Addition of External Beam to HDR Intraluminal Brachytherapy, Improve Palliation of Esophageal Cancer: A Randomized International Multi-institutional Trial | Subir Nag | |
| 192 - Adjuvant Chemoradiation for Gastric Cancer Using Epirubicin, Cisplatin and 5-FU (ECF) Before and After 3D-conformal Radiotherapy with Continuous Infusional 5-FU: A Multicentre Study of the Trans-tasman Radiation Oncology Group (TROG) | Trevor Leong | |
| 193 - Survival Impact of Neoadjuvant Radiotherapy Prior to Esophagectomy for Patients with Esophageal Cancer: A Surveillance, Epidemiology and End-results (SEER) Analysis | Ari Ballonoff | |
| 194 - Optimal SUV Threshold of Gross Tumor Volume Delineation Validated by Pathological Examination in Patients with Esophageal Cancer | Jin Yu | |
| Discussant 190-194: Gary Yang |
||
| 195 - Comparison of Preoperative and Postoperative Radiotherapy with Capecitabine in Locally Advanced Rectal Cancer: A Preliminary Report of a Phase III Randomized Trial | Sang Min Yoon | |
| 196 - A Phase I Study of Neoadjuvant Cyclooxygenase-2 Inhibition and Chemoradiation for Stage II/III Rectal Cancer |
Anuradha Chakravarthy | |
| 197 - Local Excision versus Resection in T1-2 Rectal Carcinoma: Results of a Study from the Surveillance, Epidemiology and End Results (SEER) Registry Data | Lisa Hazard | |
| Discussant 195-197: Yi-Jen Chen |
||
| 1:00 p.m. - 2:30 p.m. | Scientific Session Y Room 406 GU III - Novel Agents, Imaging and Non-Prostate GU |
Co-moderators: Ronald Ennis Arthur Hung |
| 198 - Novel Targeted Aptamer-superparamagnetic Iron Oxide Nanoparticle Bioconjugates for Combined Prostate Cancer Imaging and Therapy | Andrew Wang | |
| 199 - Novel Radiation-guided Nanoparticle Drug Delivery System for Prostate Cancer |
Jerry Jaboin | |
| 200 - Distribution of Prostate Sentinel Nodes - A Spect Derived Anatomic Atlas |
Ute Ganswindt | |
| 201 - Regarding the Focal Treatment of Prostate Cancer: Inference of the Gleason Grade from MR Spectroscopic Imaging |
Ryan Brame | |
| 202 - Phase I Study of Bi-weekly Paclitaxel and Definitive Radiation in Androgen Ablated Locally Advanced Prostate Cancer |
Nicholas Sanfilippo | |
| 203 - Statin Use and Clinical Outcomes after High Dose Radiotherapy for Prostate Cancer |
Michael Zelefsky | |
| 204 - A Phase III Randomized Trial to Assess the Efficacy of Intraoperative Steroid Use in Decreasing Acute Urinary Retention Following Transperineal Radioactive Seed Implantation for Prostate Cancer |
Michelle Mierzwa | |
| 205 - Management of Superfical Recurrence After Complete Response to Combined Modality Treatment in Bladder Cancer |
Christian Weiss | |
| 206 - Intraarterial Chemotherapy and Concurrent Radiation for Locally Advanced Bladder Cancer | Shunsuke Furutani | |
| 1:00 p.m. - 2:30 p.m. | Scientific Session Z Room 409 GYN |
Co-moderators: Paolo Montemaggi Akila Viswanathan |
| 207 - Molecular Characterization of FDG-PET Metabolic Response in Cervical Cancer | Julie Schwarz | |
| 208 - FDG Metabolic Heterogeneity of Cervical Cancer | Elizabeth Kidd | |
| 209 - Synergistic Effects of Hemoglobin and Tumor Perfusion in Tumor Control for Cervical Cancer | Nina Mayr | |
| 210 - Tumor Perfusion and Metastatic Failure in Cervical Cancer | Dongqing Zhang | |
| 211 - Expression of MDM2, p16, and HPV Status is Associated with Survival After Radiotherapy in Patients with Carcinoma of the Cervix | Corinne Doll | |
| 212 - Prospective Randomized Comparison of Monthly Fluorouracil and Cisplatin vs. Weekly Cisplatin Concurrent with Pelvic Radiotherapy and High-dose-rate Brachytherapy for Locally Advanced Cervical Cancer | Young Seok Kim | |
| 213 - Preliminary Study Comparing 10-days Continuous Hyperfractionated Accelerated Radiotherapy (CHART) vs. Conventional Radiotherapy in Conjunction with HDR Brachytherapy in Locally Advanced Cervical Cancer | Biswa Biswal | |
| 214 - Prognostic Significance of Positive Lymph Nodes in Carcinoma of the Cervix Following Radical Hysterectomy | O. Kenneth Macdonald | |
| 215 - Prognostic Factors and Adjuvant Therapy in Patients with Uterine Carcinosarcoma | Deepika Nemani | |
| 1:00 p.m. - 2:30 p.m. | Scientific Session AA Room 405 Non-Malignant |
Co-moderators: Theodore Lo Robert Lustig |
| 216 - Gamma Knife Radiosurgery (GKRS) in the Management of Trigeminal Neuralgia : Long-term Follow-up Report of 441 Cases | Deane Jacques | |
| 217 - Immortalizing Renal Allografts with Stem Cell Trasplantation Using Low-dose Irradiation as an Adjuvant to Non-myeloablative Conditioning | Vangipuram Shankar | |
| 218 - Single Institution Experience Treating 100 Vestibular Schwannomas with Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery | Bethany Anderson | |
| 219 - Radiation is Superior Over Control for Early-stage Morbus Dupuytren to Prevent Progression: Long-term Data of a Randomized Prospective Trial | Heinrich Seegenschmiedt | |
| 220 - The Role of Radiation Therapy for Progressive Airway Amyloidosis | Minh-Tam Truong | |
| 221 - Long-term Follow-up of Gamma Knife Stereotactic Radiosurgery for Trigeminal Neuralgia | Jared Adams | |
| 222 - Long-term Follow-up of Repeat Gamma Knife Stereotactic Radiosurgery for Refractory or Recurrent Trigeminal Neuralgia | Anil Dhople | |
| 223 - Intraoperative Electron Radiotherapy (IOERT) in the Management of Aggressive Fibromatosis | Falk Roeder |
|
| 224 - Radiation Therapy, Quality of Life and Cognition in Acromegalic Patients | Alphonsus van den Bergh | |
| 1:00 p.m. - 2:30 p.m. | Scientific Session BB Room 407 Normal Tissue Effects |
Co-moderators: Marikki Laiho Andy Minn |
| 225 - Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitors as Radioprotectors of Hippocampal Neurons in the Developing Brain | Dinesh Kumar Thotala | |
|
226 - Sorafenib (BAY 43-9006) Protects Normal Murine Gut From Radiation Damage |
S.J. Lunt | |
| 227 - Therapeutic Protection of Radiation-induced Whole Body Damage by the Small Soluble Peptide, EA230 | Alan Alfieri | |
| 228 - Identification of Protein Markers of Lithium Radio- and Neuroprotective Effect | Eugenia Yazlovitskaya | |
| 229 - Radioprotection of Lymphoblastoid Cells by Lentiviral Vector-based Transfer of Manganese Superoxide-dismutase (SOD2), Catalase (CAT) and Multi-drug Resistance 1 (MDR1) Genes | Marlon Veldwijk | |
| 230 - Cytosolic Phospholipase A2-dependent Signaling Protects Normal Cells from Radiation-induced Cytotoxicity | Amanda Linkous | |
| 231 - Radiation-induced Variations in Urothelial Expression of Uroplakin-III and Tight Junction Protein Occludin in Mouse Bladder | Jana Jaal | |
| 232 - Erythropoietin Attenuates Neuronal Cell Death Following Radiation | Russell Hales | |
| Discussant 225-232: Zeljko Vujaskovic |
||
| 1:00 p.m. - 2:30 p.m. | Scientific Session CC The Theater Respiratory Motion Managment |
Co-moderators: James McDonough Fanf-Fang Yin |
| 233 - Respiration Motion Prediction Using Time-delay Kernel Regression Modeling | Rebecca Seibert | |
| 234 - Clinical Evaluation of Digital Tomosynthesis for Target Localization in Breath-hold Liver Treatment | Q. Jackie Wu | |
| 235 - Evaluation of the Usefulness of Guided Breathing for Dose-rate-modulated Tracking | Yeonju Han-Oh | |
| 236 - Time and Frequency Analysis of Respiration Signals Under Different Coaching Conditions | Seth Van Liew | |
| 237 - Dosimetric Consequences of Electronic Delay on Gated Radiation Therapy (RT) | Rodney Wiersma | |
| 238 - Four-dimensional Dose Calculations to Determine the Effect of Breathing Motion on Outcomes-related Parameters for Lung Cancer Patients | Bart Lynch | |
| 239 - 4-D Radiotherapy for Lung Cancer: What is the Reduction in Lung Dose with Motion Management? | Geoffrey Hugo | |
| 240 - Respiratory Motion Changes of Lung Tumors Over the Course of Radiation Therapy | Kristin Janson | |
| 241 - Effectiveness of Abdominal Compression in Stereotactic Body Radiation Therapy (SBRT) Treatment of Lung and Liver: 4D-CT Scan Analysis of Tumor and Organ Motion at Varying Levels of Abdominal Pressure | John Heinzerling | |
| 1:00 p.m. - 2:30 p.m. | Educational Session 413 Room 511 ASTRO-ONS Lecture: Radiation Therapy and Targeted Therapies |
Vanna Marie Dest, A.P.R.N., B.C., A.O.C.N., Hospital of St. Raphael, New Haven, Conn. Paula M. Muehlbauer, M.S.N., National Institutes of Health, Arlington, Va. |
| 1:00 p.m. - 2:30 p.m. | Educational Session 414 Room 502 Multimodality and 4-D Imaging Registration and Fusion for Planning and Delivery |
Marc L. Kessler, Ph.D., University of Michigan, Ann Arbor, Mich. Laura A. Dawson, M.D., Princess Margaret Hospital, Toronto, Ontario, Canada |
| 2:45 p.m. - 4:15 p.m. | Educational Session 415 Room 404 Gastric Cancer - Current Treatment Approach and New Developments |
Leonard L. Gunderson, M.D., M.S., Mayo Clinic Cancer Center Arizona, Scottsdale, Ariz. Harvey J. Mamon, M.D., Ph.D., Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston |
| 2:45 p.m. - 4:15 p.m. | Educational Session 416 Room 515A Concurrent CT/RT for Head and Neck Cancer |
Nancy Y. Lee, M.D., Memorial Sloan-Kettering Cancer Center, New York Matthew G. Fury, M.D., Memorial Sloan-Kettering Cancer Center, New York |
| 2:45 p.m. - 4:15 p.m. | Panel 15 Room 403 Joint SNM/ASTRO - Molecular Imaging for IGRT/IMRT The growing application of molecular imaging (MI) in cancer is changing the assessment of tumor size and disease extent. It has made a particular impact on image guided radiation therapy, and an ever-growing number of groups are studying/incorporating functional image parameters such as extent of glycolysis and/or hypoxia in radiation therapy planning. This seminar seeks to address key issues concerning molecular imaging in radiation therapy planning. |
Moderator: Chaitanya Divgi, Ph.D., University of Pennsylvania, Philadelphia C. Clifton Ling, Ph.D., Memorial Sloan-Kettering Caner Center, New York The Role of Molecular Imaging in Radiation Therapy A. William Blackstock Jr., M.D., Wake Forest University School of Medicine, Winston-Salem, N.C. |
| 2:45 p.m. - 4:15 p.m. | Panel 16 Room 511 Improving Quality at the End of Life Starts at Diagnosis |
Stewart B. Fleishman, M.D., Continuum Cancer Centers Of New York: Beth Israel and St. Luke's-Roosevelt Hospitals, New York George F. Handzo, M.Div., The HealthCare Chaplaincy, New York Kathleen McDevitt, A.P.R.N., M.S.N., A.O.C.N., B.C.-P.C.M., Consultant, Marlton, N.J. Neil J. O'Connor, A.C.S.W., L.C.S.W., University of Wisconsin Hospital and Clinics, Madison, Wis. |
| 2:45 p.m. - 4:15 p.m. | Panel 17 The Theater Treatment of Re-occurrence, Re-treatment |
Moderator: Manjeet Chadha, M.D., Beth Israel Medical Center, New York Mitchell Machtay, M.D., Thomas Jefferson University Hospital, Philadelphia Samual Ryu, M.D., Henry Ford Health Hospital, Detroit Michael Zelefsky, M.D., Memorial Sloan-Kettering Cancer Center, New York |
| 2:45 p.m. - 4:15 p.m. | Panel 18 Room 408 Role of Clinical Trials in Tecnology Assessment |
Moderator: Andre Konski, M.D., M.B.A., Fox Chase Cancer Center, Philadelphia |
| Challenges in the Assessment of Emerging Technologies | Andre Konski, M.D., M.B.A., Fox Chase Cancer Center, Philadelphia |
|
| The ASTRO ETC Initiative | Paul E. Wallner, D.O., 21st Century Oncology, Moorestown, N.J. |
|
| Disparate Interests of the “Target Audience(s)” | Andre Konski, M.D., M.B.A., Fox Chase Cancer Center, Philadelphia |
|
| Selection of Appropriate End-Points | Eleanor Harris, M.D., University of Pennsylvania, Philadelphia | |
| Clinical Trial Design for Technology Assessment | Jeff M. Michalski, M.D., Washington University Medical Center, St. Louis | |
| Role of Clinical Trials in Technology Assessment | Sean Tunis, M.D., M.Sc., Center for Medical Technology Policy, Baltimore | |
Additional information will be posted periodically. Inquiries should be directed the Education Department.